Web Images Videos Maps News Shopping Gmail more »
Sign in
Scholar Home  
  Advanced Scholar Search
Scholar Preferences
Scholar Results 1 - 10 of about 32 citing Imrie: The role of high-dose chemotherapy and stem-cell transplantation in patients with.... (0.08 sec) 

[PDF] Myeloma management guidelines: a consensus report from the Scientific Advisors …


BGM Durie, RA Kyle, A Belch, W Bensinger, J … - The Hematology …, 2003 - myeloma.org
Brian GM Durie bdurie@salick.com T: 323-966-3572 F: 323-966-3685 ... Consultants & Others
Present: Philip Greipp, Robert Knight, Sean Maenpaa, Susie Novis, Lisa Paik, Michael
Rosenzweig, Iain Webb. ... Abstract These consensus guidelines have been compiled ...
Cited by 184 - Related articles - View as HTML - BL Direct - All 15 versions

High-dose therapy and autologous blood stem-cell transplantation compared with …

- ascopubs.org
JP Fermand, S Katsahian, M Divine, V … - Journal of clinical …, 2005 - jco.ascopubs.org
PATIENTS AND METHODS: One hundred ninety patients between 55 and 65 years old who
had newly diagnosed stage II or III MM were randomly assigned to receive either conventional
chemotherapy (CCT; ie, monthly courses of a regimen of vincristine, melphalan, ...
Cited by 101 - Related articles - All 6 versions

Management of multiple myeloma: a systematic review and critical appraisal of …

- wustl.edu [PDF] 
A Kumar, T Loughran, M Alsina, BGM Durie, B … - Lancet Oncology, 2003 - Elsevier
We have done a systematic review of all randomised studies in myeloma, identified through a
comprehensive search. Our aim was to investigate and critically examine the effects of various
treatment modalities on outcome in patients with multiple myeloma and address 22 ...
Cited by 64 - Related articles - All 13 versions

Results of a multicenter randomized phase II trial of thalidomide and prednisone …


AK Stewart, CI Chen, K Howson-Jan, D White, J Roy, … - Clinical Cancer Research, 2004 - AACR
We report a multicenter, randomized phase II trial conducted to assess the tolerability of combined
thalidomide and prednisone maintenance in multiple myeloma. Eligibility required administration
of melphalan (200 mg/m 2 ) with blood stem cell support within 1 year of treatment onset ...
Cited by 47 - Related articles - All 7 versions

High-dose therapy with single autologous transplantation versus chemotherapy for …

- ufl.edu [PDF] 
J Koreth, CS Cutler, B Djulbegovic, R Behl, RL … - Biology of Blood and …, 2007 - Elsevier
Myeloablative high-dose therapy and single autologous stem cell transplantation (HDT) is frequently
performed early in the course of multiple myeloma, supported by some randomized controlled
trials (RCTs) indicating overall survival (OS) and progression-free survival (PFS) benefit ...
Cited by 40 - Related articles - All 9 versions

Management of multiple myeloma and related-disorders: guidelines from the Italian …

- haematologica.com [PDF] 
G Barosi, M Boccadoro, M Cavo, P Corradini, M … - Haematologica, 2004 - haematologica.org
From the Laboratorio di Epidemiologia Clinica, IRCCS Policlinico S.Matteo, Pavia, Italy (GB,
MM); Divisione Universitaria di Ematologia, Azienda Ospedaliera San Giovanni Battista,
Turin, Italy (MB, MM); Istituto di Ematologia ed Oncologia Medica “Seragnoli”, Università ...
Cited by 31 - Related articles - BL Direct - All 19 versions

A meta-analysis on data from 575 patients with multiple myeloma randomly …


V Lévy, S Katsahian, JP Fermand, JY Mary, S Chevret - Medicine, 2005 - journals.lww.com
Abstract: Long-term results of high-dose therapy followed by autologous stem cell transplantation
(HDT-ASCT) as the first-line treatment for patients with myeloma are still poorly reported. To gain
further insight in the long-term benefits of first-line HDT- ASCT compared with ...
Cited by 22 - Related articles - BL Direct - All 4 versions

Cure of multiple myeloma–more hype, less reality


P Hari, MC Pasquini, DH Vesole - Bone Marrow Transplantation, 2005 - nature.com
Randomized studies have firmly established the role of autologous transplant as initial therapy
in multiple myeloma (MM). Indeed, MM has emerged as the commonest indication for autologous
SCT in North America. The conceptual basis for high-dose therapy is the goal of complete ...
Cited by 19 - Related articles - BL Direct - All 4 versions

Multiple myeloma: comparison of two dose-intensive melphalan regimens (100 vs …


A Palumbo, S Bringhen, A Bertola, F Cavallo, P Falco, … - Leukemia, 2003 - nature.com
Several trials have shown the superior impact of high-dose melphalan (usually 200 mg/m 2 ,
MEL200) vs standard therapy in myeloma patients. Intermediate-dose melphalan (100 mg/m
2 , MEL100) is also superior to the standard dose, but has not been clinically compared ...
Cited by 16 - Related articles - BL Direct - All 3 versions

Thalidomide-based treatment for HIV-associated multiple myeloma: a case report


DM Aboulafia - AIDS READER-NEW YORK-, 2003 - medscape.com
The spectrum of hematologic and immunologic abnormalities induced by HIVinfection is
broad. Although the incidence of HIV-associated B-cell neoplasms has increased, relatively few
cases of multiple myeloma have been reported, and even fewer cases have detailed ...
Cited by 11 - Related articles - BL Direct - All 2 versions


Result Page: 

1

2

3

4

Next


 


Go to Google Home - About Google - About Google Scholar

©2009 Google